You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Type 1 Issues Articles
Popular Type 1 Issues Articles
Highly Recommended Type 1 Issues Articles
Send a link to this page to your friends and colleagues.
Flamel Technologies and Novo Nordisk announced that they will collaborate on developing Basulin, a long-acting, once-a-day formulation of human insulin that can be used by people with type 1 and 2 diabetes.
According to a Flamel Technologies press release, the terms of the agreement specify that Novo will have exclusive worldwide development and marketing rights to Basulin, while Flamel receives up-front licensing fees of $5 million, including $1 million received in early December 1999, as well as $37 million in milestone payments and royalties of future product sales. Novo will subsidize all clinical trials and ?product development of Basulin.
"As a leading provider of insulin products for the treatment of diabetes, Novo Nordisk is the ideal development and marketing partner for Basulin," says Gerard Soula, president and CEO of Flamel.
In preclinical tests, Basulin provided continuous, 24-hour coverage compared to standard 12-hour coverage provided by currently marketed products. A phase 1 clinical trial using Basulin is underway in the United Kingdom and results are expected early this year.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.